发布时间：2026-05-06 09:07 Significant unmet need remains for 85% of lupus patients whose disease includes skin manifestations, often associated with substantial physical and psychosocial burden
Enpatoran, an oral TLR7/8 inhibitor, is designed for lupus patients with active cutaneous manifestations, with the goal of broadening the treatment paradigm beyond the current standards
ELOWEN is a global Phase 3 program evaluating enpatoran’s impact on both skin and systemic symptoms in patients with lupus and potential links between skin and systemic disease activity



DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations.

“People living with lupus continue to face significant challenges in achieving disease contr
=*=*=*=*=*=
当前为第1/10页
下一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页